PMID- 25936347 OWN - NLM STAT- MEDLINE DCOM- 20160926 LR - 20220419 IS - 1878-5492 (Electronic) IS - 0966-3274 (Linking) VI - 32 IP - 3 DP - 2015 Jun TI - Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results. PG - 151-5 LID - S0966-3274(15)00026-X [pii] LID - 10.1016/j.trim.2015.04.004 [doi] AB - BACKGROUND: Therapeutic antibodies used to desensitize patients awaiting a human leukocyte antigen (HLA) or ABO-mismatched graft are suspected to interfere with the lymphocytotoxicity crossmatch (LCT-XM) test when they are present in the tested sera because of their potential ability to activate or inhibit the complement. METHODS: The most frequent therapeutic antibodies (Abs) used in desensitization protocols (intravenous immunoglobulins, rituximab, basiliximab, eculizumab, antithymocyte globulin) were added to a negative- or a positive-control serum at various concentrations, and tested in vitro in a LCT-XM test. RESULTS: Rituximab turned the LCT-XM positive on B cells at 0.2 mug/mL and antithymocyte globulin turned the LCT-XM positive with T and B cells at 20 mug/mL and 200 mug/mL, respectively. Treatment with dithiothreitol sera, supplemented with rituximab (0.2 and 2 mug/mL) and antithymocyte globulins (20 and 200 mug/mL), partially or totally reduced this positive interference. Intravenous immunoglobulin, eculizumab, and basiliximab did not trigger any interference with the negative control serum. In a positive LCT-XM, eculizumab did not annihilate activation of the rabbit complement. Intravenous immunoglobulins (25 g/L) could partially or totally reduced lysis score of positive crossmatch with weak lysis scores. CONCLUSION: If eculizumab within the serum did not annihilate rabbit complement activation and basiliximab did not interfere with the crossmatch reaction, treatments based on rituximab, antithymocyte globulin and intravenous immunoglobulins need to be taken into account when interpreting a positive or negative crossmatch test. CI - Copyright (c) 2015 Elsevier B.V. All rights reserved. FAU - Milongo, David AU - Milongo D AD - Department of Nephrology and Organ Transplantation, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France. Electronic address: davidmilongo@gmail.com. FAU - Vieu, Guillaume AU - Vieu G AD - Laboratoire d'immunologie, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France; Laboratoire d'Immunogenetique Moleculaire, EA 3034, Universite Toulouse III Paul-Sabatier, 118 Route de Narbonne, 31062 Toulouse, France. Electronic address: vieu.g@chu-toulouse.fr. FAU - Blavy, Sarah AU - Blavy S AD - Laboratoire d'immunologie, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France. Electronic address: sarahblavy@yahoo.fr. FAU - Del Bello, Arnaud AU - Del Bello A AD - Department of Nephrology and Organ Transplantation, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France. Electronic address: delbello.a@chu-toulouse.fr. FAU - Sallusto, Federico AU - Sallusto F AD - Department of Urology, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France. Electronic address: sallusto.f@chu-toulouse.fr. FAU - Rostaing, Lionel AU - Rostaing L AD - Department of Nephrology and Organ Transplantation, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France; Universite Toulouse III Paul-Sabatier, 118 Route de Narbonne, 31062 Toulouse, France. Electronic address: rostaing.l@chu-toulouse.fr. FAU - Kamar, Nassim AU - Kamar N AD - Department of Nephrology and Organ Transplantation, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France; Universite Toulouse III Paul-Sabatier, 118 Route de Narbonne, 31062 Toulouse, France. Electronic address: kamar.n@chu-toulouse.fr. FAU - Congy-Jolivet, Nicolas AU - Congy-Jolivet N AD - Laboratoire d'immunologie, CHU Rangueil, 1 Avenue du Professeur Jean Poulhes, 31059 Toulouse, France; Laboratoire d'Immunogenetique Moleculaire, EA 3034, Universite Toulouse III Paul-Sabatier, 118 Route de Narbonne, 31062 Toulouse, France. Electronic address: congy.n@chu-toulouse.fr. LA - eng PT - Journal Article DEP - 20150430 PL - Netherlands TA - Transpl Immunol JT - Transplant immunology JID - 9309923 RN - 0 (ABO Blood-Group System) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antilymphocyte Serum) RN - 0 (HLA Antigens) RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Isoantibodies) RN - 0 (Recombinant Fusion Proteins) RN - 4F4X42SYQ6 (Rituximab) RN - 9927MT646M (Basiliximab) RN - A3ULP0F556 (eculizumab) SB - IM MH - ABO Blood-Group System/immunology MH - Animals MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Antibody-Dependent Cell Cytotoxicity MH - Antilymphocyte Serum/therapeutic use MH - Basiliximab MH - Blood Grouping and Crossmatching/*methods MH - Complement Activation/drug effects MH - Diagnostic Errors/*prevention & control MH - HLA Antigens/immunology MH - Humans MH - Immunoglobulins, Intravenous/therapeutic use MH - Isoantibodies/*metabolism MH - Rabbits MH - Recombinant Fusion Proteins/therapeutic use MH - Rituximab/therapeutic use OTO - NOTNLM OT - Desensitization OT - Drug interference OT - HLA OT - Kidney transplantation OT - Lymphocytotoxicity crossmatch OT - Therapeutic antibodies EDAT- 2015/05/06 06:00 MHDA- 2016/09/27 06:00 CRDT- 2015/05/05 06:00 PHST- 2015/02/04 00:00 [received] PHST- 2015/04/22 00:00 [revised] PHST- 2015/04/24 00:00 [accepted] PHST- 2015/05/05 06:00 [entrez] PHST- 2015/05/06 06:00 [pubmed] PHST- 2016/09/27 06:00 [medline] AID - S0966-3274(15)00026-X [pii] AID - 10.1016/j.trim.2015.04.004 [doi] PST - ppublish SO - Transpl Immunol. 2015 Jun;32(3):151-5. doi: 10.1016/j.trim.2015.04.004. Epub 2015 Apr 30.